Purdue Petition Seeks FDA Commitment To “Adapted” Studies For OxyContin Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says a generic should be equivalent or better than reformulated OxyContin on all the tests to ensure it has equivalent abuse-deterrent capabilities.
You may also be interested in...
FDA’s Opioid To-Do List Could Redefine Pain Market For Brands, Generics
Supporters of narrowing opioid drugs’ non-cancer pain indication tell FDA that pain patients often suffer the consequences of addiction and misuse.
FDA Opioid Guidance Is Silent On Generics, Cautions That Addicts Can Erase Labeling
Draft guidance on abuse-deterrent opioids notes that labeling claims may be revised if abusers outwit the abuse-resistant technology; the agency’s evaluation of generic-related citizen petitions continues.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.